Early safety check of UCB3101 in healthy people ends early
Knowledge-focused
Terminated
This study aimed to see if a single dose of UCB3101 is safe and tolerable in healthy adults aged 18 to 65. A total of 167 participants were planned, but the trial was terminated early. The main focus was on tracking any side effects or serious medical events after the dose.
Phase: PHASE1 • Sponsor: UCB Biopharma SRL • Aim: Knowledge-focused
Last updated Apr 29, 2026 00:50 UTC